Biogen Inc.

Visual Financials
Company Name: Biogen Inc
Ticker Symbol: BIIB
CIK Number: 0000875045
WWW Address: http://www.biogen.com
CEO: Mr. Michel Vounatsos
No. of Employees: 7,400
Common Issue Type: CS
Business Description:Biogen Idec Inc., is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia.

 
Industry Information: DRUGS - Biotechnology [more like this]
 Price  Day Change  Bid  Ask  Open  High  Low  Volume 
 233.935 Up 0.045 233.88 234.0 236.26 228.17 223.85 788163
 Market Cap (mil) Shares Outstanding (mil) Beta EPS DPS P/E Yield 52-Wks-Range
 45,358.5 193.9 0.00 21.63 0.00 10.6 0.0 388.67 - 216.12
KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close224.35$
PE Ratio - LTM10.6
Market Capitalisation45,358.5mil
Latest Shares Outstanding193.9mil
Earnings pS (EPS)21.63$
Dividend pS (DPS)0.00¢
Dividend Yield0.0%
Dividend Payout Ratio%
Revenue per Employee1,724,731$
Effective Tax Rate0.2%
Float193.2mil
Float as % of Shares Outstanding1.0%
Foreign Salesmil
Domestic Salesmil
Selling, General & Adm/tive (SG&A) as % of Revenue0.20%
Research & Devlopment (R&D) as % of Revenue0.20%
Gross Profit Margin86.5%
EBITDA Margin52.9%
Pre-Tax Profit Margin0.0%
Assets Turnover55.0%
Return on Assets (ROA)18.1%
Return on Equity (ROE)34.5%
Return on Capital Invested (ROCI)24.0%
Current Ratio2.3
Leverage Ratio (Assets/Equity)1.9
Interest Cover30.4
Total Debt/Equity (Gearing Ratio)0.46
LT Debt/Total Capital31.0%
Working Capital pS22.41$
Cash pS0.00$
Book-Value pS71.33$
Tangible Book-Value pS21.73$
Cash Flow pS30.70$
Free Cash Flow pS26.69$
KEY FIGURES (LTM): Price info
Price/Book Ratio3.18
Price/Tangible Book Ratio0.00
Price/Cash Flow7.4
Price/Free Cash Flow8.5
P/E as % of Industry Group124.0%
P/E as % of Sector Segment25.0%
 
Balance Sheet (at a glance) in Millions
DIVIDEND INFO
Type of Payment-
Dividend Rate0.00
Current Dividend Yield0.0
5-Y Average Dividend Yield0.0
Payout Ratio0.0
5-Y Average Payout Ratio0.0
Share price performance previous 3 years

Share price performance intraday

 
PRICE/VOLUMEHighLowClose% Price Chg% Price Chg vs. Mkt.Avg. Daily VolTotal Vol
1 Week---2.31,537,0385,716,673
4 Weeks236.89218.88226.23-0.81,601,35330,425,724
13 Weeks330.10216.12307.93-27.12,591,274163,250,296
26 Weeks345.00216.12316.73-29.21,929,685239,281,022
52 Weeks388.67216.12303.29-26.01,667,797416,949,411
YTD345.00216.12--26.41,999,043215,896,645
Moving Average5-Days10-Days10-Weeks30-Weeks200-DaysBeta (60-Mnth)Beta (36-Mnth)
224.02224.90230.20286.47300.480.000.00
 
GROWTH RATES5-Year
Growh
R² of 5-Year Growth3-Year
Growth
Revenue0.140.30.08
Income0.190.50.08
Dividend0.0
Capital Spending0.21NA0.19
R&D5.49NA0.85
Normalized Inc.18.94NA15.56
 
CHANGESYTD vs.
Last YTD
Curr Qtr vs.
Qtr 1-Yr ago
Annual vs.
Last Annual
Revenue %-11.0-11.0-13.3
Earnings %41.041.011.8
EPS %43.243.214.3
EPS $0.540.540.72
 
SOLVENCY RATIOS
SHORT-TERM SOLVENCY RATIOS (LIQUIDITY)
Net Working Capital Ratio17.18
Current Ratio2.3
Quick Ratio (Acid Test)1.8
Liquidity Ratio (Cash)1.45
Receivables Turnover5.6
Average Collection Period64
Working Capital/Equity33.3
Working Capital pS22.09
Cash-Flow pS30.14
Free Cash-Flow pS25.82
FINANCIAL STRUCTURE RATIOS
Altman's Z-Score Ratio1.75
Financial Leverage Ratio (Assets/Equity)0.5
Debt Ratio23.5
Total Debt/Equity (Gearing Ratio)0.46
LT Debt/Equity0.46
LT Debt/Capital Invested0.0
LT Debt/Total Liabilities100.0
Interest Cover30.4
Interest/Capital Invested1.54
 
VALUATION RATIOS
MULTIPLES
PQ Ratio0.00
Tobin's Q Ratio1.74
Current P/E Ratio - LTM10.60
Enterprise Value (EV)/EBITDA5.52
Enterprise Value (EV)/Free Cash Flow9.94
Dividend Yield0.0
Price/Tangible Book Ratio - LTM0.00
Price/Book Ratio - LTM3.18
Price/Cash Flow Ratio7.4
Price/Free Cash Flow Ratio - LTM8.5
Price/Sales Ratio0.00
P/E Ratio (1 month ago) - LTM35.4
P/E Ratio (26 weeks ago) - LTM26.3
P/E Ratio (52 weeks ago) - LTM27.5
5-Y High P/E Ratio19.1
5-Y Low P/E Ratio8.9
5-Y Average P/E Ratio19.6
Current P/E Ratio as % of 5-Y Average P/E-30
P/E as % of Industry Group124.0
P/E as % of Sector Segment25.0
Current 12 Month Normalized P/E Ratio - LTM33.2
PER SHARE FIGURES
LT Debt pS28.21
Current Liabilities pS15.66
Tangible Book Value pS - LTM21.73
Book Value pS - LTM71.33
Capital Invested pS97.87
Cash pS - LTM0.00
Cash Flow pS - LTM30.70
Free Cash Flow pS - LTM26.69
Earnings pS (EPS)21.63
 
OPERATING RATIOS
PROFITABILITY RATIOS
Free Cash Flow Margin39.41
Free Cash Flow Margin 5YEAR AVG29.91
Net Profit Margin0.3
Net Profit Margin - 5YEAR AVRG.0.3
Equity Productivity1.03
Return on Equity (ROE)0.3
Return on Equity (ROE) - 5YEAR AVRG.0.3
Capital Invested Productivity0.71
Return on Capital Invested (ROCI)0.2
Return on Capital Invested (ROCI) - 5YEAR AVRG.0.2
Assets Productivity0.50
Return on Assets (ROA)0.2
Return on Assets (ROA) - 5YEAR AVRG.0.2
Gross Profit Margin86.5
Gross Profit Margin - 5YEAR AVRG.0.9
EBITDA Margin - LTM52.9
EBIT Margin - LTM45.3
Pre-Tax Profit Margin0.4
Pre-Tax Profit Margin - 5YEAR AVRG.0.4
Effective Tax Rate0.0
Effective Tax Rate - 5YEAR AVRG.0.0
EFFICIENCY RATIOS
Cash Conversion Cycle
Revenue per Employee1,724,731
Net Income per Employee568,038
Average Collection Period
Receivables Turnover5.6
Day's Inventory Turnover Ratio
Inventory Turnover2.0
Inventory/Sales6.9
Accounts Payble/Sales2.75
Assets/Revenue2.00
Net Working Capital Turnover3.10
Fixed Assets Turnover0.76
Total Assets Turnover0.5
Revenue per $ Cash10.99
Revenue per $ Plant3.74
Revenue per $ Common Equity1.03
Revenue per $ Capital Invested0.71
Selling, General & Adm/tive (SG&A) as % of Revenue15.7
SG&A Expense as % of Revenue - 5YEAR AVRG.1.0
Research & Devlopment (R&D) as % of Revenue20.1
R&D Expense as % of Revenue - 5YEAR AVRG.20.1

  


Your Recent History
NASDAQ
BIIB
Biogen Inc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.